Lorcaserin, a 5HT2C agonist, decreases nicotine self-administration in female rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 3, 2011, Pages 890-896

  Levin, Edward D ^a   Johnson, Joshua E ^a   Slade, Susan ^a   Wells, Corinne ^a   Cauley, Marty ^a   Petro, Ann ^a   Rose, Jed E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LORCASERIN; NICOTINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 1 METHYL 1H 3 BENZAZEPINE; 8-CHLORO-2,3,4,5-TETRAHYDRO-1-METHYL-1H-3-BENZAZEPINE; BENZAZEPINE DERIVATIVE; NICOTINIC AGENT; SEROTONIN 2 AGONIST; SEROTONIN 2C RECEPTOR;

ADULT ANIMAL; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SELF ADMINISTRATION; FEMALE; LOCOMOTION; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RAT; SEDATION; ANIMAL; DRUG EFFECT; FOOD; MOTIVATION; MOTOR ACTIVITY; PSYCHOLOGICAL ASPECT; REWARD; SMOKING CESSATION; SPRAGUE DAWLEY RAT; TOBACCO DEPENDENCE;

ANIMALS; BEHAVIOR, ANIMAL; BENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOOD; MOTIVATION; MOTOR ACTIVITY; NICOTINE; NICOTINIC AGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2C; REWARD; SELF ADMINISTRATION; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 80052166129     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.183525     Document Type: Article

References (13)

1. 2c receptors in the ventral tegmental area. Neuroscience 146:286-297.
2. Crofton KM, Howard JL, Moser VC, Gill MW, Reiter LW, Tilson HA, and MacPhail RC (1991) Interlaboratory comparison of motor activity experiments: implications for neurotoxicological assessments. Neurotoxicol Teratol 13:599-609.
3. 2C receptor knockout mice. Neuropharmacology 57:259-267.
4. Glassman AH, Stetner F, Walsh BT, Raizman PS, Fleiss JL, Cooper TB, and Covey LS (1988) Heavy smokers, smoking cessation, and clonidine: results of a double-blind, randomized trial. JAMA 259:2863-2866.
5. Higgins GA, Silenieks L, Rizos Z, Noble K, and Fletcher PJ (2010) The selective 5-HT2C receptor agonist, lorcaserin, reduces indices of nicotine reward as well as food intake in the rat, in Proceedings of the 40th Annual Meeting of the Society for Neuroscience; 2010 Nov 13-17; San Diego, CA. Abstract 168.19, Society for Neuroscience, Washington, DC.
6. Levin ED, Pruitt M, Cousins V, Slade S, Wells C, Cauley M, Hampton D, and Rose JE (2010) Histamine H1 antagonist treatment with pyrilamine reduces nicotine self-administration in rats. Eur J Pharmacol 212:551-558.
7. Levin ED, Slade S, Johnson M, Petro A, Horton K, Williams P, Rezvani AH, and Rose JE (2008) Ketanserin, a 5-HT2 receptor antagonist, decreases nicotine self-administration in rats. Eur J Pharmacol 600:93-97.
8. McEvoy JP, Freudenreich O, Levin ED, and Rose JE (1995) Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology 119:124-126.
9. Rose JE, Behm FM, Westman EC, and Kukovich P (2006) Precessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob Res 8:89-101.
10. Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, Chen RR, Park DM, Prieto EB, Gallardo CS, et al. (2008) Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J Med Chem 51:305-313.
11. Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR, and APD356-004 Study Group (2009) Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity 17:494-503.
12. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR, and Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group (2010) Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 363:245-256.
13. 2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 325:577-587. (Pubitemid 351574813)